Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated glomerular filtration rate (eGFR) of \<50 ml/min/1.73m2~* At least one of the following risk factors: diabetes mellitus, age at least 75 years, anemia (baseline hematocrit value less or equal 39% for men and less or equal 36% for women), congestive heart failure class III or IV by New York Heart Association classification, history of pulmonary edema.~Exclusion Criteria:~* Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g. known hypersensitivity or allergy to class of drugs or the investigational product~* History of allergy to rabbits~* Current treatment with N-acetylcysteine, sodium bicarbonate, fenoldopam, mannitol (not applicable to mannitol serving as excipient in other medical drugs), dopamine or theophylline~* Women who are pregnant or breast feeding~* Multiple myeloma~* Acute decompensated heart failure (requiring hospital admission and treatment with supplemental oxygen, diuretics and/or vasodilator therapy) within two weeks prior to the date of coronary angiography~* Acute myocardial infarction (ST elevation or non-ST elevation myocardial infarction) within two weeks prior to the date of coronary angiography~* Dialysis~* Exposure to iodinated contrast media within seven days prior to the date of coronary angiography.~* Participation in another study with investigational drug within the 30 days preceding and during the present study~* Previous enrolment into the current study~* Enrolment of the investigators and their family members

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conestat alfa (Type: ACTIVE_COMPARATOR): Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
- Sodium chloride 0.9% (Type: PLACEBO_COMPARATOR): Intravenous injection of sodium chloride 0.9%.

Based on this trial design, predict the completion outcome and termination type (if applicable).